ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjögren’s syndrome"

  • Abstract Number: 2634 • ACR Convergence 2024

    Transcriptomic Stratification Predicts Response to Rituximab, Abatacept or the Association of Hydroxychloroquine and Leflunomide in 3 Randomized Controlled Clinical Trials in Sjögren’s Disease

    Baptiste Chevet1, Valerie Devauchelle2, Elena Pontarini3, Valentin Baloche4, Michele Bombardieri5, Simon Bowman6, Michael Barnes7, Antoine Sreih8, Jinqi Liu8, Sheila Kelly9, Antonia Christodoulou8, Hussain Badani10, Philippe Moigeon11, Laurence LAIGLE12, Perrine Soret13, Christelle Le dantec14, Jacques-Olivier Pers15, Marta Alarcon-Riquelme16, Guillermo Barturen17, Xavier Mariette18, Joel Van Roon19, Raphaele Seror20, Gaetane Nocturne18, Divi Cornec21 and Nathan Foulquier14, and PRECSEADS Clinical Consortium and NECESSITY consortium, 1University Hospital of Brest, Brest, France, 2UBO, Brest, France, 3William Harvey Research Institute, London, United Kingdom, 4University Medical Center, Utrecht, Utrecht, Netherlands, 5Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 6Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom, 7William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, 8Bristol Myers Squibb, Princeton, NJ, 9Bristol Myers Squibb, Doylestown, PA, 10Bristol Myers Squibb, Lawrence Township, NJ, 11Servier Laboratories, France, Gif sur Yvette, France, 12Servier Laboratories, France, SURESNES, France, 13Servier, Paris-Saclay, Paris, Ile-de-France, France, 14LBAI. UMR 1227, University of Brest, Brest, France, 15University of Brest, Brest, France, 16Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 17Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 18Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 19University Medical Center Utrecht, Utrecht, Netherlands, 20Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 21Service de Rhumatologie, CHU de Brest, Brest, France

    Background/Purpose: Sjögren’s disease (SjD) is a clinically and biologically heterogeneous disease. To date, no phase-III trial showed efficacy in reducing the symptoms or systemic activity…
  • Abstract Number: 0152 • ACR Convergence 2024

    Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases

    Janett Riega Torres1, Karina Palomo-Arnaud2, Gabriel Figueroa-Parra1, Fernando Morales Wong1, Jesús Hernán González Cortés1, Jesus Mohamed Hamsho1, Jorge Esquivel-Valerio1, Dionicio Galarza-Delgado3 and Karim Mohamed Noriega1, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 3UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology.  Retinal toxicity is an unwanted side effect…
  • Abstract Number: 1411 • ACR Convergence 2024

    Impact of Patient and Physician Alignment on Sjögren’s Disease Severity, a Real-World Survey on Patients’ Clinical Outcomes and Health-Related Quality of Life

    Wan Fai Ng1, Coralie Bouillot2, NICOLA MASSEY3, Megan Hughes3, Victoria Barton3, Giorgio Castellano3, Ana Barat4, Gayle Kenney5 and Jessica Marvel6, 1Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, 2Sjögren Europe, Switzerland, Switzerland, 3ADELPHI REAL WORLD, BOLLINGTON, United Kingdom, 4Novartis Ireland Ltd, Dublin, Ireland, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis, East Hanover, NJ

    Background/Purpose: Sjögren’s disease (SjD) has a high disease burden in affected patients, with no licensed treatments currently available. The Clinical EULAR Sjögren’s syndrome disease activity…
  • Abstract Number: 1427 • ACR Convergence 2024

    Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study

    Sophia G. Liva1, fudan Zheng1, Jocelyn H. Leu2, Kathy Sivils3, Keying Ma1, He Li4, Steven Leonardo5, Kim Lo1, Jada Idokogi1, Kim Campbell1 and Jonathan J. Hubbard1, 1Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, 3Johnson & Johnson Innovative Medicine, Edmond, OK, 4Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, 5Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA

    Background/Purpose: Sjögren’s disease (SjD) is a chronic, progressive autoimmune disease characterized by aberrant B lymphocyte activity, elevated IgG production, and the presence of IgG autoantibodies…
  • Abstract Number: 2289 • ACR Convergence 2024

    Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study

    Benjamin Zuckerman1, Alasdair Warwick2, art Schuermans3, Mark Gibson4, Ioasaf Karafotias5, Zijing Yang1, Carine moezinia6, Mark Russell7, Chris Wincup8, James Galloway9 and Sizheng Zhao10, 1King's College London, London, England, United Kingdom, 2University college London, London, United Kingdom, 3KU Leuven, Leuven, Belgium, 4King's College London, Newmarket, United Kingdom, 5King's College London, London, United Kingdom, 6univerity college hospital, London, United Kingdom, 7King's College London, London, United Kingdom, 8King's College Hospital, London, United Kingdom, 9Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 10Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom

    Background/Purpose: The pathophysiology of primary Sjögren’s disease involves the interaction of genetic, epigenetic, and environmental factors. With limited treatment options for severe disease, a detailed understanding…
  • Abstract Number: 2305 • ACR Convergence 2024

    Anti-Ku Positivity in Primary Sjögren’s Disease Is Associated with a More Systemic Active Disease

    Marie ROBERT1, Yann Nguyen2, Yurdagül Uzunhan3, Benjamin Terrier4, Yves Allenbach5, Alain Meyer6, Jacques-Eric Gottenberg7, JEROME HADJADJ8, Zahir Amoura9, ARNAUD HOT10, Eléonore Bettacchioli11, Elisabeth Aslangul12, Rakiba Belkhir13, Frederic Desmoulins14, Elisabeth Bergé14, Pascale Chrétien15, Pascale Roland-Nicaise16, Claire Goulvestre17, Jean-Luc Charuel18, Benoit Nespola19, Nicole Fabien20, Eric Ballot21, Gaetane Nocturne14, Xavier Mariette14, Samuel Bitoun1 and Raphaele Seror22, 1Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 2Université Paris Saclay, Clichy, Ile-de-France, France, 3Service de Pneumologie, Hôpital Avicenne, AP-HP, Bobigny, France, 4Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 5Service de Médecine interne et immunologie clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, 6UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, 7Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 8Service de Médecine interne, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, 9French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France, 10Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, 11Service de Rhumatologie, CHU de Brest, Brest, France, 12Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, 13Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, 14Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 15Laboratoire d'immunologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, France, 16Laboratoire d'immunologie, Hôpital Bichat, AP-HP, Paris, France, 17Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 18Laboratoire d'immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, 19Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 20Laboratoire d'immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France, 21Laboratoire d'immunologie, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, 22Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France

    Background/Purpose: Sjögren’s disease (SjD) is an autoimmune disease characterized by a wide range of symptoms, and 30% to 60% of patients developed systemic manifestations. The…
  • Abstract Number: 2664 • ACR Convergence 2024

    BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease

    Laura Bucci1, Melanie Hagen2, Sebastian Boeltz2, Danae-Mona Noethling2, Tobias Rothe2, Maria Gabriella Raimondo1, Carlo Tur1, Andreas Wirsching1, Jochen Wacker1, Aline Bozec1, Georg Schett3 and Ricardo Grieshaber-Bouyer2, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
  • Abstract Number: 0154 • ACR Convergence 2024

    Chronic Sinusitis Predicting Interstitial Lung Disease in Sjögren’s Syndrome: A Comprehensive USA Population Study (2004-2024)

    Brian Schonewald1, Ross summer2, Giorgos Loizidis2 and Christopher Xie3, 1Thomas Jefferson University Hospital, Ardmore, PA, 2Thomas Jefferson University, Philadelphia, PA, 3Thomas Jefferson University, Philadelphia

    Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder primarily affecting the exocrine glands, but it also impacts various parts of the respiratory system, including…
  • Abstract Number: 1412 • ACR Convergence 2024

    Survival and Predictive Markers of Prognosis in Patients with Cancer Occurrence After Sjögren Syndrome: A Long-term Observational Study

    Yezi Peng1, Jiana Chen2, Yafei Ren3, Dan Yang2, Xiangyi Shen4, Xu Jiang5 and Huaxia Yang2, 1Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dong Cheng Qu, Beijing, China (People's Republic), 2Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Department of Rheumatology and immunotogy,Affiliated Hospital of Guilin Medical University,Guilin, China, Guangxi, China (People's Republic), 4Tsinghua University, Beijing, China, 5National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Background/Purpose: Patients with Sjögren syndrome (SS) have been reported to have a higher risk of cancer than the general population, and malignancy constitutes one of…
  • Abstract Number: 1428 • ACR Convergence 2024

    A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)

    Wolfgang Hueber1, Raphaele Seror2, Raphael Porcher3, Gabriel Baron4, Linchen He5, Wen-Lin Luo5, Xavier Mariette6 and Peter Gergely1, and the members of the NECESSITY IMI2 consortium, 1Novartis Pharma, Basel, Switzerland, 2Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 3Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 4Hôpitaux Universitaires Paris-Sud (AP-HP), Paris, Ile-de-France, France, 5Novartis Pharma, East Hanover, NJ, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Two randomized controlled phase 2 trials in patients with active Sjogren’s disease (SjD) were recently completed, the LOUiSSe trial assessing the Bruton Tyrosine kinase…
  • Abstract Number: 2290 • ACR Convergence 2024

    Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology

    Yukitomo Hagiwara1, Goh Murayama2, Taiga Kuga2, Yujin Nishioka2, Takumi Saito2, Yu Yamaji2, Tomoko Miyashita2, Makio Kusaoi3, Ken Yamaji2 and Naoto Tamura2, 1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan

    Background/Purpose: Primary Sjögren's syndrome (pSS) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
  • Abstract Number: 2306 • ACR Convergence 2024

    Deconstruction and Reconstruction of Sjögren’s Disease: AMP®-AIM Partnership

    Astrid Rasmussen1, A. Darise Farris1, Alan Baer2, Blake M. Warner3, Christopher Lessard1, Stephen Shiboski4 and Caroline Shiboski4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3National Institutes of Health, Bethesda, MD, 4University of California San Francisco, San Francisco, CA

    Background/Purpose: The Accelerating Medicines Partnership (AMP®) is a public-private partnership with the goal of transforming the current model for developing new diagnostics and treatments by…
  • Abstract Number: PP09 • ACR Convergence 2024

    Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS

    Robert Fearon, Sjögren's Foundation, Reston, VA

    Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…
  • Abstract Number: 0443 • ACR Convergence 2024

    Significance of anti-Ro52 Antibody in Pregnancy Complicated with Anti-SS-A Antibody Positive Rheumatic Disease Patients

    Hiromi Shimada1, Rina Mino2, taichi miyagi3, Yusuke Ushio4, Koichi Sugihara5, Mao Mizusaki2, Hayamasa yamaguchi2, Naoto Manabe2, Shusaku Nakashima1 and Hiroaki Dobashi1, 1Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 2Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, 4Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 5Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan

    Background/Purpose: Anti-SS-A antibodies are associated with neonatal lupus erythematosus and congenital heart block (CHB). Ro/SS-A autoantigen is comprised of 52kDa Ro (Ro52) and 60kDa Ro…
  • Abstract Number: 1413 • ACR Convergence 2024

    Pilot Trial of Ustekinumab for Primary Sjogren’s Syndrome

    Ummara Shah1 and Andrea Coca2, 1University of Rochester, Webster, NY, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Sjogren’s Syndrome (SS) is a chronic autoimmune disease characterized by keratoconjunctivitis sicca and xerostomia. Currently there is no approved systemic treatment for primary SS. …
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology